Home/Pipeline/Novel approach to tumor/host interactions

Novel approach to tumor/host interactions

Oncology

Pre-clinicalActive

Key Facts

Indication

Oncology

Phase

Pre-clinical

Status

Active

Company

Genesis Therapeutics

About Genesis Therapeutics

Genesis Therapeutics is a private, AI-native drug discovery company pioneering the use of generative AI and physics-based models to invent novel small molecule drugs. Its core technology is the GEMS (Genesis Exploration of Molecular Space) platform, anchored by foundation models like the 3D diffusion model Pearl, which is used to design compounds against challenging targets. The company has secured significant upfront payments through multi-target collaborations with partners like Gilead and Incyte, while also advancing a wholly-owned pipeline in oncology and immunology. Genesis operates at the intersection of cutting-edge AI research and experimental biology, with teams in the Bay Area, New York City, and a wet lab in San Diego.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active